Radiation pneumonitis and early circulatory cytokine markers.

Radiation pneumonitis is a distinct clinical entity that differs from other pulmonary symptoms such as allergic pneumonitis, chemical pneumonitis, or pneumonia by various infectious agents. Recent research has supported the mechanism of cellular interaction between lung parenchymal cells and circulating immune cells mediated through a variety of cytokines including proinflammatory cytokines, chemokines, adhesion molecules, and profibrotic cytokines. Identifying reliable biomarkers for radiation pneumonitis will allow us to identify individuals at risk for pneumonitis before or during the early stage of therapy. Prospective blood sampling, scoring of respiratory symptoms, and chest imaging were conducted for patients receiving thoracic radiotherapy for malignancy. Serial plasma specimens were analyzed for circulating cytokine changes before, during, and up to 12 weeks after radiation. Radiation pneumonitis was diagnosed using National Cancer Institute (NCI) common toxicity criteria. Cytokine analysis was assayed for interleukin 1alpha (IL-1alpha), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), E-selectin, L-selectin, transforming growth factor beta1 (TGF-beta1), and basic fibroblast growth factor (bFGF) using enzyme linked immmunosorbant assay (ELISA). Twenty-four patients had clinical follow-up longer than 12 months after radiotherapy. Thirteen had symptomatic pneumonitis (NCI grade 2). The peak incidence of symptoms was between 6 and 13 weeks after radiotherapy. Six patients had only radiographic infiltrates (NCI grade 1). Five patients did not have clinical or radiographic pneumonitis. Both IL-1alpha and IL-6 levels were significantly higher before, during, and after radiotherapy for those who had pneumonitis. The pattern of changes of MCP-1, E-selectin, L-selectin, TGF-beta1, and bFGF varied, but none of these cytokines correlated with radiation pneumonitis. Analysis of a panel of circulating cytokines with different putative functions in radiation pulmonary injury identified IL-1alpha and IL-6 as early circulating cytokine markers for radiation pneumonitis.

[1]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[2]  P. Fitzpatrick,et al.  Radiation pneumonitis: experience following a large single dose of radiation. , 1978, International journal of radiation oncology, biology, physics.

[3]  P. Okunieff,et al.  Circulating IL-6 as a predictor of radiation pneumonitis. , 2001, International journal of radiation oncology, biology, physics.

[4]  J. Elias,et al.  IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. , 1990, Journal of immunology.

[5]  K. Shin,et al.  The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocol , 1993 .

[6]  N. Mendenhall,et al.  Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast‐conserving surgery and postoperative irradiation , 1994, Cancer.

[7]  S. McDonald,et al.  A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. , 1995, International journal of radiation oncology, biology, physics.

[8]  H. Merte,et al.  Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Athanassiou,et al.  18 Randomized phase III trial of radiation ± amifostine in patients with advanced stage lung cancer , 1999 .

[10]  J. Zaunders,et al.  Radiation Pneumonitis: A Possible Lymphocyte-mediated Hypersensitivity Reaction , 1993, Annals of Internal Medicine.

[11]  E. Kovacs.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. , 1991, Immunology today.

[12]  Ke Xiong,et al.  Regulation of chemokine‐induced transendothelial migration of T lymphocytes by endothelial activation: differential effects on naive and memory T cells , 2000, Journal of leukocyte biology.

[13]  M. Schuyler,et al.  Mediators of hypersensitivity pneumonitis. , 2000, The Journal of laboratory and clinical medicine.

[14]  J. Elias,et al.  Differential interleukin 1 elaboration by unfractionated and density fractionated human alveolar macrophages and blood monocytes: relationship to cell maturity. , 1985, Journal of immunology.

[15]  S. Antonia,et al.  Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung. , 1995, Seminars in oncology.

[16]  B. Kimler,et al.  Release of interleukin-1 by human alveolar macrophages after in vitro irradiation. , 1993, Radiation research.

[17]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[18]  L. Aarden,et al.  Interleukin 6 is involved in interleukin 1‐induced activities , 1988, European journal of immunology.

[19]  J. Elias,et al.  Human alveolar macrophage and blood monocyte interleukin-6 production. , 1990, American journal of respiratory cell and molecular biology.

[20]  M. Yoshinaga,et al.  Possible role of l‐selectin in T lymphocyte alveolitis in patients with active pulmonary sarcoidosis , 2000, Clinical and experimental immunology.

[21]  S. McDonald,et al.  Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. , 1995, International journal of radiation oncology, biology, physics.

[22]  R. Clough,et al.  Plasma transforming growth factor β1 as a predictor of radiation pneumonitis , 1997 .

[23]  P. Hiemstra,et al.  Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD , 2000, The Journal of pathology.

[24]  P. Rubin,et al.  Alterations in the expression of chemokine mRNA levels in fibrosis-resistant and -sensitive mice after thoracic irradiation. , 1998, Experimental lung research.

[25]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Gross.  Pulmonary effects of radiation therapy. , 1977, Annals of internal medicine.

[27]  P. Maasilta,et al.  Bronchoalveolar lavage fluid findings following radiotherapy for non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.

[28]  W. Rom,et al.  Molecular regulation of IL-6 activation by asbestos in lung epithelial cells: role of reactive oxygen species. , 1997, Journal of immunology.